Smart Matrix® News

 

21  Apr 2017

Press release CSL Behring Announcement  – please click on the link below:

SML CSL Behring Announcement

3 Apr 2017

Press release Collagen Solution Announcement  – please click on the link below:

SML Collagen Solutions Announcement

Press release Board Changes – please click on the link below:

SML Board Changes

 

20 March 2017

Press release – please click on the link below:

Smart Matrix – CEO Appointment

30 January 2017

Andy Hill appointed to the Board.

3 January 2017

Andy Hill joins Smart Matrix Limited as CEO.

August 2016

Smart Matrix Limited closes another successful fundraising round with £1.3m coming from existing shareholders.

19 May 2016

Appointment of Swen Lorenz to the Board of Smart Matrix Limited.

3 May 2016

Appointment of Mark Brown to the Board of Smart Matrix Limited.

Mar 2016

Completed pre-clinical studies at Northwick Park Institute for Medical Research.

31 Dec 2015

Completion of 12 month follow up to last patient in the clinical trial of Smart Matrix®.

Sept 2015

Commenced detailed programme of follow-on pre-clinical studies.

2 Apr 2015

The Data Monitoring Committee meets and confirms the safety of Smart Matrix®.

24 Feb 2015

Appointment of Dr Fulvio Urso-Baiarda as Medical Advisor.

26 Jan 2015

Appointment of Dr Lilian Hook as Chief Scientific Officer to SML.

3 Jan 2015

Enrolment of the final patient into the clinical trial of Smart Matrix®.

29 Oct 2014

A new licence agreement is signed with Smart Matrix Intellectual Property Limited extending SML’s intellectual property rights.

19 Aug 2014

The first patient was treated in the clinical trial of Smart Matrix®.

4 Jun 2014

A letter with a notification of No Objection was received from the MHRA.

24 Apr 2014

Application for the pre-clinical assessment of Smart Matrix® – acknowledgement of notification received from the MHRA.

27 Mar 2014

Completion of £300,000 (net) investment by Reyker Nominees Ltd on behalf of Downing LLP.

23 Aug 2013

The Company is pleased to report closure of Tranche 2 of its fundraising with equity receipts in excess of £3.4 million.

9 Aug 2013

First Work Order signed with Clinical Research Organisation (CRO) in contemplation of clinical trials commencement.

3 May 2013

Master Service Agreement signed with our chosen CRO following a thorough selection process.

6 Feb 2013

Jeremy Curnock Cook appointed to the Board of Smart Matrix Limited.

6 Feb 2013

European Medicines Agency confirm Company’s qualification as SME.

11 Dec 2012

Manufacturing Services Agreement signed with manufacturer for the GMP manufacturing of Smart Matrix®.

13 Jan 2012

The Board of Smart Matrix Limited is pleased to announce the approval of its Investment Memorandum.

9 Dec 2011

The Board of Smart Matrix Limited is pleased to announce the commencement of trading, the establishment of its corporation framework and the receipt of £200,000 of equity funds.

15 Sep 2011

The Company receives advance assurance from HMR&C that it is a qualifying company for EIS purposes and that, providing the Company continues to meet its obligations in this regard, its shares will qualify for EIS relief.

18 Apr 2011

Date of incorporation of Smart Matrix Limited.

 


Smartmatrix award

Smart Matrix Limited - Winners of the 2016 International Life Sciences Award for Best Medical Implant & Technology Research Group

SmartMatrix Limited – Winner of the 2016 ACQ5 Global Award for UK Gamechanger of the Year – Ms Leonor Stjepic

Smart Matrix Limited – Winner of the 2016 ACQ5 Global Award for UK Gamechanger of the Year – Ms Leonor Stjepic

SmartMatrix Limited – Winner of the 2016 ACQ5 Global Award for UK - Company of the Year

Smart Matrix Limited – Winner of the 2016 ACQ5 Global Award for UK - Company of the Year

Corporate LiveWire Healtcare and Life Sciences Awards 2016 Winner

Smart Matrix Limited – Winner of the 2016 Healthcare and Life Sciences Award